We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Quotient Bioresearch Presents Comprehensive Drug Development Capabilities via New Company Website
Product News

Quotient Bioresearch Presents Comprehensive Drug Development Capabilities via New Company Website

Quotient Bioresearch Presents Comprehensive Drug Development Capabilities via New Company Website
Product News

Quotient Bioresearch Presents Comprehensive Drug Development Capabilities via New Company Website


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "Quotient Bioresearch Presents Comprehensive Drug Development Capabilities via New Company Website"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

The new website highlights the company’s key focus areas of Chemistry and Metabolism, Clinical and Bioanalytical Sciences and provides visitors with a wealth of information on Quotient’s innovative range of service capabilities for advancing drug development.
 
Quotient Bioresearch partners its clients with a unique offering of leading-edge technologies and services for all stages of early drug development which results in reduced timelines, complexity and costs. Quotient is uniquely placed to offer its clients significant benefits via a range of innovative services including 14C labelling, metabolism studies, Phase I/IIa clinical drug development and bioanalysis for small and large molecules.

Quotient’s Chairman and Chief Executive Officer Paul Cowan commented, “We are delighted to announce the launch of our new website which highlights Quotient’s unique capabilities and scientific expertise across our focussed service areas. The site provides our clients with an in-depth understanding of how Quotient Bioresearch is uniquely positioned to offer services on a standalone basis or within an integrated bespoke development programme that simplifies the development process and offers reduced timelines and costs.”
The new website contains comprehensive information on a number of integrated service offerings that are completely unique to Quotient Bioresearch. Quotient’s innovative Synthesis-to-Clinic™ capability is a seamless service from the synthesis of a compound into the clinic for pharmaceutical and biotechnology clients engaged in studies containing radiolabelled compounds. This integrated service simplifies the procurement of regulatory and non-regulatory studies, resulting in shorter development times and efficiencies.

The company’s unique Translational Pharmaceutics™ capability is also highlighted on the website. Translational Pharmaceutics is an integrated formulation development, drug product manufacturing and clinical testing platform which increases the efficiency and precision with which an optimised oral drug product can be identified for further development, resulting in significantly reduced development timelines and associated cost savings.

Advertisement